Ann: Opthea Reports Positive Phase 1/2A Clinical Results, page-17

You may be right Whytee but the top 20 previous to this capital raising held approximately 70% of the share register (with this percentage no doubt set to increase given retail investors are barely getting a look in here) and had not been doing a lot of selling despite a substantial appreciation in share-price over the last 18 months. I would also assume given the offer was oversubscribed several times that the company could have been pretty choosy as to who came on the register. Sounds like existing institutions got the opportunity to top up with some new ones coming onboard. If the future is as bright as some think for this company maybe they will be in for the long haul. Regardless there will be a pullback in share price at some stage. It will be interesting to see what the share price drivers will be for this company over coming months